Cyfuse Biomedical KK (FSE:4892) Debt-to-EBITDA : N/A (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FSE:4892 Cyfuse Biomedical KK FSE:4892
52 GF Score
Price 円561.00
GF Value 円2,202.02
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Cyfuse Biomedical KK Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cyfuse Biomedical KK's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was 円849.7 Mil. Cyfuse Biomedical KK's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was 円383.3 Mil. Cyfuse Biomedical KK's annualized EBITDA for the quarter that ended in Jun. 2026 was 円0.0 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Cyfuse Biomedical KK's Debt-to-EBITDA or its related term are showing as below:

FSE:4892' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.33   Med: -1.77   Max: 3.37
Current: -1.6

During the past 6 years, the highest Debt-to-EBITDA Ratio of Cyfuse Biomedical KK was 3.37. The lowest was -2.33. And the median was -1.77.

FSE:4892's Debt-to-EBITDA is ranked worse than
100% of 675 companies
in the Drug Manufacturers industry
Industry Median: 1.63 vs FSE:4892: -1.60

Cyfuse Biomedical KK  (FSE:4892) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Cyfuse Biomedical KK Debt-to-EBITDA Related Terms

Cyfuse Biomedical KK Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Cyfuse Biomedical KK's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyfuse Biomedical KK Debt-to-EBITDA Chart

Cyfuse Biomedical KK Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial 3.37 -2.33 -1.70 -1.04 -1.84

Cyfuse Biomedical KK Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.87 -1.26 -3.85 -1.42 N/A

FSE:4892 vs ZTS: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyfuse Biomedical KK Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cyfuse Biomedical KK's Debt-to-EBITDA falls into.


FSE:4892
52GF Score
Cyfuse Biomedical KK FSE:4892
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyfuse Biomedical KK Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cyfuse Biomedical KK's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(669.664 + 642.336) / -711.528
=-1.84

Cyfuse Biomedical KK's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(849.66 + 383.34) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is Cyfuse Biomedical KK (FSE:4892) Overvalued in 2026?

Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued. The current stock price of 円561.00 is trading 74.5% below its estimated GF Value™ of 円2,202.02. GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.

Key valuation signals for FSE:4892:

  • Debt-to-EBITDA: N/A
  • GF Value™: 円2,202.02 vs. price of 円561.00 (74.5% below fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the FSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cyfuse Biomedical KK Business Description

Other Exchanges 4892:Japan
Address 3-5-27 Mita, 1st Floor, Sumitomo Real Estate Tokyo Mita South Tower, Minato-ku, Tokyo, JPN, 108-6301
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
52GF Score

Get the complete analysis for FSE:4892

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円561.00
Price
円2,202.02
GF Value